Price checked Oct 26, 2026

Menopause, weight and GLP-1s: which kind of care fits you?

Seven questions about your periods, symptoms, insurance and GLP-1 use sort the menopause telehealth platforms into the kinds that may fit you: ones that bill insurance, cash platforms with FDA-approved hormone therapy, non-hormonal options, and ones that also prescribe GLP-1s. It is not a diagnosis, it gives no doses, and nothing you enter leaves your browser.

Last updated: 2026-10-01 · First published: 2026-09-29 · Platforms checked Sep 29, 2026

For men: GLP-1s and testosterone.

The self-check

Seven questions, about two minutes. The last one is about your health history, and it decides whether an online platform is a sensible place to start at all.

1. How old are you?
2. What are your periods like?
3. What bothers you most?

Pick all that apply.

4. Do you have health insurance?
5. What kind of treatment would you rather look at?
6. Are you taking or considering a GLP-1 (Wegovy, Zepbound or similar)?
7. Have you ever had any of these?

Answer each one.

Breast cancer
A blood clot (in a leg or the lungs)
A stroke
Liver disease
Vaginal bleeding with no known cause

Your answers stay in this browser. Nothing is sent or saved.

Why does weight change around menopause?

Less because the scale jumps and more because the body's make-up shifts. In the SWAN study of 1,246 women, fat gain sped up from 1.0% to 1.7% a year as the transition began, while lean (muscle) mass started to shrink, and a later SWAN analysis found deep belly fat grew about 6% a year during the transition [1][2]. Hormone therapy treats symptoms such as hot flashes; a Cochrane review of 28 trials found it has no effect on body weight [3]. The full evidence, including what is known about hormone therapy with a GLP-1, is on why weight changes in menopause.

Fat gain speeds up as menopause arrivesFat gain speeds up asmenopause arrivesAverage change per year in fat and lean (muscle)mass, 1,246 women in the SWAN study, measured byDXA scanFat mass, years before the transition+1.0% a yearFat mass, during the transition+1.7% a yearLean mass, years before the transition+0.2% a yearLean mass, during the transition−0.2% a yearSource: Greendale GA et al., JCI Insight, 2019 (doi10.1172/jci.insight.124865). The transition = 2 years before to1.5 years after the final period; afterwards both changes wereclose to zero.weighweekly.com
SWAN, yearly change in fat and lean mass before and during the menopause transition. Open the chart on its own (SVG)

How do I know if it is perimenopause or menopause?

Menopause is the point when you have gone 12 months in a row without a period; perimenopause is the years before it, when periods often become irregular [4]. The average age of menopause in the US is around 51 to 52 [4][5]. Hot flashes and night sweats can last for years: in SWAN, the median was 7.4 years in total and 4.5 years after the final period [6]. A clinician can tell you where you are, especially after a hysterectomy or with a hormonal IUD, when periods are no guide.

Why does the self-check ask about breast cancer, clots, stroke, liver disease and bleeding?

Because FDA labeling lists each of them as a reason not to use systemic estrogen, the main menopausal hormone therapy [7]. Online platforms work from questionnaires and short visits, so anyone with one of these in their history is better served by a doctor who can examine them and see their records first. That is why a "yes" to any of them replaces every platform suggestion with that advice.

Can I be treated for menopause and take a GLP-1 at the same time?

Several menopause platforms prescribe both, so one clinician can look at your symptoms and your weight together; they are listed in the platform comparison. Research on using hormone therapy and a GLP-1 together is limited to observational studies, summarized on the evidence page. Whether a combination suits you is a decision for your clinician.

The rest of the menopause guide

Sources

  1. Greendale GA et al. Changes in body composition and weight during the menopause transition. JCI Insight, 2019. 10.1172/jci.insight.124865
  2. Greendale GA et al. Changes in regional fat distribution and anthropometric measures across the menopause transition. J Clin Endocrinol Metab, 2021. 10.1210/clinem/dgab389
  3. Kongnyuy EJ et al. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev, 1999 (stable since 2011). 10.1002/14651858.CD001018
  4. NICHD (NIH). About menopause (reviewed 2021). www.nichd.nih.gov/health/topics/menopause/conditioninfo
  5. HHS Office on Women's Health. Menopause basics (updated 2026). www.womenshealth.gov/menopause/menopause-basics
  6. Avis NE et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med, 2015. 10.1001/jamainternmed.2014.8063
  7. Divigel (estradiol gel) prescribing information, FDA label revised 02/2026 (DailyMed). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59e610dc-883e-4f07-9ec6-a5841b0bf9fb

A weekly GLP-1 email

One short email a week on GLP-1 treatment: what the trials and prescribing labels describe at each stage, and changes in cost and access. General information, not tied to a particular medication or dose. For the trial average for your own medication, use the curve calculator.

No spam. Unsubscribe any time. Educational information only, not medical advice.